[1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. DOI: 10.3322/caac.2126210.3322/caac.21262]Search in Google Scholar
[2. Sobin LH, Gospodariwicz M, Wittekind C. TNM classification of malignant tumors [Internet]. 7th ed. Vol. UICC International Union Agains Cancer. Wiley- Blackwell; 2009. 262-265 p. Available from: http:// www.uicc.org/tnm]Search in Google Scholar
[3. Hadadi L., Sus Ioana, Lakatos Eva Katalin, Serban Razvan Constantin, Scridon Alina, Demjen Zoltan, et al. Platelet indices and platelet-to-lymphocyte ratio predict coronary chronic total occlusion in patients with acute ST-elevation myocardial infarction. Rev Romana Med Lab. 2015;23(4):407-14. DOI: 10.1515/rrlm-2015-004110.1515/rrlm-2015-0041]Search in Google Scholar
[4. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Oca-a A, et al. Prognostic role of neutrophil- to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun;106(6):dju124. DOI: 10.1093/jnci/dju12410.1093/jnci/dju124]Search in Google Scholar
[5. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, et al. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World J Urol. 2017;35(1):121-30. DOI: 10.1007/s00345-016-1848-910.1007/s00345-016-1848-9]Search in Google Scholar
[6. Ertas IE, Gungorduk K, Akman L, Ozdemir A, Terek MC, Ozsaran A, et al. Can preoperative neutrophil: lymphocyte and platelet:lymphocyte ratios be used as predictive markers for lymph node metastasis in squamous cell carcinoma of the vulva? Eur J Obstet Gynecol Reprod Biol. 2013 Nov;171(1):138-42. DOI: 10.1016/j.ejogrb.2013.08.02310.1016/j.ejogrb.2013.08.023]Search in Google Scholar
[7. Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, et al. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. Urol Oncol. 2016 Nov;34(11):483.e17-483.e24. DOI: 10.1016/j.urolonc. 2016.05.013]Search in Google Scholar
[8. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013 Jul 23;109(2):416-21. DOI: 10.1038/bjc.2013.33210.1038/bjc.2013.332]Search in Google Scholar
[9. Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, et al. The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. Eur Urol Focus. 2016;2(1):79-85. DOI: 10.1016/j. euf.2015.03.001]Search in Google Scholar
[10. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013 Dec;190(6):1999-2004. DOI: 10.1016/j. juro.2013.06.082]Search in Google Scholar
[11. Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017 Mar;35(3):337-353. DOI: 10.1007/s00345-016-1826-210.1007/s00345-016-1826-2]Search in Google Scholar
[12. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, Briganti A, Roupret M, et al. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. Minerva Urol Nefrol. 2016 Aug;68(4):381-95.]Search in Google Scholar
[13. Favilla V, Castelli T, Urzì D, Reale G, Privitera S, Salici A, et al. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single- institutional longitudinal study. Int Braz J Urol. 2016 Aug;42(4):685-93. DOI: 10.1590/S1677-5538. IBJU.2015.0243]Search in Google Scholar
[14. Babjuk M, Bohle, A., Burger M, Comperat E, Kaasinen E, Palou J, et al. Guidelines on non-muscle-invasive Bladder Cancer (Ta,T1 and CIS). In: EAU Guidelines. European Association of Urology; 2015.]Search in Google Scholar
[15. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006 Mar;49(3):466-77. DOI: 10.1016/j. eururo.2005.12.031]Search in Google Scholar
[16. Vartolomei MD, Balan D, Stefan AS, Tilinca MC, Voidezan S, Chibelean C, et al. 169 Long term follow-up after TUR-B for NMIBC. An external validation of EORTC risk tables. Eur Urol Suppl. 2015;14(5):e169.10.1016/S1569-9056(15)30362-6]Search in Google Scholar
[17. Orsola A, Werner L, de Torres I, Martin-Doyle W, Raventos CX, Lozano F, et al. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br J Cancer. 2015 Feb 3;112(3):468-74. DOI: 10.1038/bjc.2014.63310.1038/bjc.2014.633445365425535728]Search in Google Scholar
[18. Rouprêt M, Seisen T, Compérat E, Larré S, Mazerolles C, Gobet F, et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol. 2013 Jun;189(6):2069-76. DOI: 10.1016/j.juro.2012.11.12010.1016/j.juro.2012.11.12023201497]Search in Google Scholar
[19. Viers BR, Boorjian SA, Frank I, Tarrell RF, Thapa P, Karnes RJ, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. Eur Urol. 2014 Dec;66(6):1157-64. DOI: 10.1016/j.eururo.2014.02.04210.1016/j.eururo.2014.02.04224630414]Search in Google Scholar
[20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74. DOI: 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.01321376230]Search in Google Scholar
[21. De Larco JE, Wuertz BRK, Furcht LT. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8. Clin Cancer Res Off J Am Assoc Cancer Res. 2004 Aug 1;10(15):4895-900. DOI: 10.1158/1078-0432.CCR-03-076010.1158/1078-0432.CCR-03-076015297389]Search in Google Scholar
[22. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, et al. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. Medicine (Baltimore). 2015 Oct;94(42):e1861. DOI: 10.1097/ MD.000000000000186110.1097/MD.0000000000001861462081826496339]Search in Google Scholar
[23. Ferro M, Giuberti G, Zappavigna S, Perdonà S, Facchini G, Sperlongano P, et al. Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin- C in bladder cancer cells with different mechanisms. Oncol Rep. 2012 Feb;27(2):409-15.]Search in Google Scholar
[24. Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson JJ, Long SR, et al. Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009 Jun 15;115(12):2660-70. DOI: 10.1002/cncr.2431110.1002/cncr.24311276920519455607]Search in Google Scholar
[25. Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011 Dec 1;117(23):5392-401. DOI: 10.1002/cncr.26198 10.1002/cncr.26198320614521780079]Search in Google Scholar